Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll
about
Current and emerging treatment options in the management of lupusPatient-reported outcomes in lupus clinical trials with biologics.Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Neutrophils in animal models of autoimmune diseaseSuppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateThe impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.Belimumab in the management of systemic lupus erythematosus - an update.Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.A critical review of clinical trials in systemic lupus erythematosus.Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.B Cell-Based Treatments in SLE: Past Experience and Current Directions.Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study.Lupus community panel proposals for optimising clinical trials: 2018.Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.Targeting B Cells and Plasma Cells in Autoimmune Diseases.Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
P2860
Q26741266-C89FF96D-1374-41DE-B76E-0C1AF953053BQ30391564-C28F786C-5DF0-4482-B49C-7943791BD7B2Q31160251-3B376A61-4D5A-456F-8639-80D57151893DQ33433447-76D539E0-4C3A-42FB-B3CC-C61261E1E9D7Q33698040-94B21DB8-0FD6-4B13-9705-71324E6081A7Q33731705-CE9B6EBC-449D-4EFB-9981-98092C8A0D4BQ36271212-E9536517-6133-47DD-974C-5068D72C79E6Q36902110-3AAD34DC-C194-4D19-A695-34C7FA9E06A9Q37358946-C91219E0-8218-4040-AE89-0EAA0E2723E9Q37709763-68A718BE-E106-43C5-8855-7CD5D1B5BBD9Q38385493-9E0F4A02-9D86-4728-8F2D-40A8C6CCCA12Q38408710-B5917483-7941-4E5C-A178-26914E75E6EBQ38605480-6D216E0C-2235-46C7-BD5F-293F5AABAACFQ38690844-6F5D429B-B558-411C-907F-031E3CDB3D86Q38794663-3E0F56D9-854D-4BDF-88C9-83E33E4B6B9AQ38799791-DD5ADE31-EF8C-4460-9AAE-578941F7F562Q38810737-AA40B360-0765-46D5-B9AC-D7CA583714A6Q38813080-825F354F-9DDF-4860-8852-7E554BADECEEQ38833868-9AE64ECF-4E27-4782-8688-85937CA2B45FQ38833876-F64A01DA-F7D8-4488-9B47-83864DD8CFBFQ38840646-05A0EB60-7748-4381-8600-11739104A5CDQ38864797-B2EDD0FF-97BB-4DC7-9DD4-8D32C6386A97Q38961202-3CE5B337-199F-43E4-9F1A-8836AA9BC7AFQ38979169-56719C6D-7FC3-42C7-A2FA-CB1939A704C6Q39053147-CAC46FA9-863C-4ADE-9FD4-875EE14EE69DQ39088664-CDCF25DC-0F5A-4CE5-8A1A-E629CE776E7BQ39379152-5C9677AD-B273-4F48-A68B-4476D97038B4Q40496217-4830BB7B-F7EA-4E10-99B7-E283E40DF233Q41418810-5E8771B8-073B-44AF-A771-AEE10A7346E1Q42368413-605B16A5-6C57-4EFB-87CE-DDB0679EE2D1Q46803412-3897C797-9F11-4CFA-AC5C-65576F07722AQ47095865-EAC66481-9C8F-4D04-BAFB-E66D997A6E0FQ47552016-836E7D0F-56B1-461F-961F-B9568FF72AA0Q47660691-AAD524F4-209B-4D6D-90BD-F37DCB6C80BEQ50053733-C651D042-3222-4B96-8069-48AE82461BF5Q51607670-F751BCC8-6D73-4C4E-ADA9-3AB4E13B54EAQ52320880-4FF04D0E-AF55-4912-803B-76A3C669D9C2Q53035901-84381763-DE21-4A26-9FDC-6302CE848B54Q55234556-38623671-5BAA-47FF-95D0-8CBF048E44BCQ57495648-D2F807D5-A56D-47AB-B110-DAC46F833664
P2860
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of subcuta ...... double-blind, placebo-controll
@en
type
label
Efficacy and safety of subcuta ...... double-blind, placebo-controll
@en
prefLabel
Efficacy and safety of subcuta ...... double-blind, placebo-controll
@en
P2093
P2860
P1476
Efficacy and safety of subcuta ...... lind, placebo-controlled study
@en
P2093
J T Merrill
M Morgan-Cox
P W Anderson
P-Y Berclaz
R F van Vollenhoven
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-207654
P407
P50
P577
2015-08-20T00:00:00Z